研究发现，前列腺癌的 ADT 通过增加淀粉样斑块和血脑屏障通透性来增加阿尔茨海默病的风险。 Study finds ADT for prostate cancer raises Alzheimer's risk by increasing amyloid plaques and blood-brain barrier permeability.
据奥古斯塔大学的一项研究表明,前列腺癌的标准激素治疗,即基缺乏疗法 (ADT),可能会增加患有癌症的男性患阿尔茨海默病的风险. A study from Augusta University suggests that standard hormone therapy treatment for prostate cancer, known as Androgen Deprivation Therapy (ADT), may increase the risk of Alzheimer's disease in men with the cancer. ADT 可降低睾丸激素，但也可去除雄激素，雄激素是淀粉样蛋白代谢的关键调节因子，导致更多的淀粉样蛋白留下来形成斑块——这是阿尔茨海默病的标志。 ADT reduces testosterone, but also removes androgens, key regulators of amyloid metabolism, leading to more amyloid left to form plaques - a hallmark of Alzheimer's. 研究发现,ADT治疗使血液脑屏障更容易渗透,导致更多的炎症和损伤。 The study found that ADT treatment makes the blood-brain barrier more permeable, leading to more inflammation and damage. 然而,ADT和NDAizumab(一种用于治疗多发性硬化症和克罗恩病的药物)相结合,减少了炎症,改善了动物模型的认知功能。 However, a combination of ADT and natalizumab, a drug used to treat multiple sclerosis and Crohn's disease, reduced inflammation and improved cognitive function in animal models.